Optipharm.CO.LTD (153710) — Cash Flow-to-Debt Ratio
Optipharm.CO.LTD (153710) has a Cash Flow-to-Debt Ratio of -0.03x as of December 2025, meaning its operating cash flow of ₩-408.70 Million could theoretically repay 0% of its total liabilities (₩15.37 Billion) in one year. Explore Optipharm.CO.LTD strategic investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Optipharm.CO.LTD Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Optipharm.CO.LTD across 11 annual periods. Also explore Optipharm.CO.LTD balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Optipharm.CO.LTD (2015–2025)
Year-by-year debt coverage analysis for Optipharm.CO.LTD. For market capitalisation and broader financial context, see Optipharm.CO.LTD market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.10x | ₩-1.55 Billion | ₩15.37 Billion | ▼ -171.5% |
| 2024 | -0.04x | ₩-595.50 Million | ₩15.98 Billion | ▲ +69.4% |
| 2023 | -0.12x | ₩-1.72 Billion | ₩14.13 Billion | ▲ +39.0% |
| 2022 | -0.20x | ₩-2.43 Billion | ₩12.17 Billion | ▼ -3.7% |
| 2021 | -0.19x | ₩-1.97 Billion | ₩10.21 Billion | ▲ +10.0% |
| 2020 | -0.21x | ₩-1.62 Billion | ₩7.54 Billion | ▼ -392.7% |
| 2019 | 0.07x | ₩447.47 Million | ₩6.11 Billion | ▼ -56.2% |
| 2018 | 0.17x | ₩1.20 Billion | ₩7.20 Billion | ▲ +352.4% |
| 2017 | 0.04x | ₩260.86 Million | ₩7.06 Billion | ▼ -69.6% |
| 2016 | 0.12x | ₩861.36 Million | ₩7.08 Billion | ▲ +312.5% |
| 2015 | -0.06x | ₩-751.51 Million | ₩13.12 Billion | — |